Innovative Tryton Side Branch Stent Recognized with the Premier Technology Breakthrough Award

DUBLIN, Ohio, September 19, 2017 — Cardinal Health and Tryton Medical Inc. today announced that the Tryton coronary Side Branch Stent was recognized by Premier Inc., a leading healthcare improvement company, with the prestigious Technology Breakthrough Award. Premier’s Technology Breakthrough Award is granted to cutting-­edge products that significantly advance healthcare in terms of safety, clinical outcomes and/or operational efficiency.

The Tryton Side Branch Stent, the first dedicated bifurcation device to receive regulatory approval in the U.S., is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥2.5mm stent). Cordis, Cardinal Health’s interventional vascular business, is the exclusive U.S. distributor of the Tryton Side Branch Stent.

The Tryton Side Branch Stent System is built using proprietary Tri-­ZONE® technology to offer a dedicated strategy for treating bifurcation lesions. Tryton’s cobalt chromium stent is deployed in the side branch artery using a standard single wire balloon-­expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel. The Tryton Side Branch Stent has now been used to treat more than 12,000 patients worldwide.

“Cordis, along with Tryton Medical, is pleased to receive Premier’s award that recognizes the positive impact the Tryton Side Branch Stent is making in healthcare by offering physicians and their patients a new and innovative treatment option,” said Peter Van Haur, Vice President, North America Sales and Marketing, Cordis. “Cordis is known for delivering ground-­breaking technology and we are proud to offer our customers across the U.S. the Tryton Side Branch Stent.”

“Tryton is proud to be the first company to obtain FDA approval for the treatment of coronary bifurcated lesions, so often left only partially addressed using standard stents. This Award validates the clinical need for our dedicated, predictable solution for coronary bifurcations and the novelty of the Tryton Side Branch Stent,” said Richard Davis, interim CEO & co-­founder, Tryton Medical.

About Tryton Medical, Inc.

Tryton Medical, Inc., located in Durham, N.C., is the leading developer of novel stent systems for the treatment of bifurcation lesions. The company was founded in 2003 by Aaron V. Kaplan, M.D., professor of medicine at the Geisel School of Medicine/Dartmouth-­Hitchcock Medical Center, to develop stents for the definitive treatment of bifurcation lesions. For more information please visit www.trytonmedical.com and follow the company on Twitter at @TrytonMedical1.

About Cardinal Health

Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products and pharmaceuticals and cost-­effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. Because Cardinal Health helps ensure pharmacists and the consumers they serve have access to medications they need while working to help prevent prescription drug diversion, the company and its education partners created Generation Rx, a national program to help prevent the misuse of prescription medications. Backed by nearly 100 years of experience, with approximately 50,000 employees in nearly 60 countries, Cardinal Health ranks #15 on the Fortune 500. For more information, visit cardinalhealth.com, follow @CardinalHealth on Twitter and connect on LinkedIn at linkedin.com/company/cardinal-­health.